Tenax Therapeutics’ Phase 3 PH-HFpEF Trial Looms as Potential Market Catalyst

Tenax Therapeutics is set to disclose Phase 3 LEVEL study results this month, evaluating an oral levosimendan pill for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The chronic condition features stiff left-ventricular muscles that raise lung pressure, causing breathlessness and fatigue. The trial’s main goal is a statistically significant gain of about 15 metres in a six-minute walk test after 12 weeks, with 20-25 metres considered a robust outcome, and a secondary focus on quality-of-life scores via the KCCQ.

Analysts note the market potential of 2 million U.S. patients, estimating peak sales between $2.5 billion and $5.4 billion, plus additional global revenue. Tenax’s entire pipeline hinges on this single indication, and the company has no fallback product. A press release is expected within three weeks, followed by a presentation at the European Society of Cardiology on Aug. 29.